Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant pseudomonas aeruginosa

A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.

• Autores: Munita, Jose M.; Aitken, Samuel L.; Miller, William R.; Perez, Federico; Rosa, Rossana; Shimose, Luis A.; Lichtenberger, Paola N.; Abbo, Lilian M.; Jain, Rupali; Nigo, Masayuki; Wanger, Audrey; Araos, Rafael; Tran, Truc T.; Adachi, Javier; Rakita, Robert; Shelburne, Samuel; Bonomo, Robert A.; Arias, Cesar A.
• Tipo de recurso: Article of journal
• Fecha de publicación: 2020
• Institución: Universidad El Bosque
• Repositorio: Repositorio U. El Bosque
• Idioma: eng
• OAI Identifier: oai:repositorio.unbosque.edu.co:20.500.12495/3679
• Acceso en línea: http://hdl.handle.net/20.500.12495/3679; https://doi.org/10.1093/cid/cix014; https://repositorio.unbosque.edu.co
• Palabra clave: Ceftolozane; Carbapenem resistant; P. aeruginosa; Multidrug resistant
• Rights: openAccess
• License: Acceso abierto